Dear followers, have you seen this video about $1,35B palace, supposingly, build by Putin (use subtitles or find translated version in your country)? Can you imagine how many longevity researches, clinical trials to fight aging could be done for at least 10% of this amount? Please post your comments what longevity researches & trials should be immediately funded?

https://youtu.be/ipAnwilMncI

Effect of Vitamin D3 Supplements on Development of Advanced Cancer
A Secondary Analysis of the VITAL Randomized Clinical Trial

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2773074?resultClick=1

https://jamanetwork.com/journals/jamanetworkopen/

From the Emmy-winning Greg Daniels (The Office, Parks & Rec) comes a hilarious new sci-fi comedy. In the future people can upload their consciousness to a luxurious digital afterlife. When party boy Nathan gets uploaded to a virtual resort he meets the down-to-earth Nora who starts as his customer service “angel”, but becomes so much more as she helps him find friendship, love and purpose.

https://www.amazon.com/Upload-Season-1/dp/B0858YGKZ4

Aging is often perceived as a degenerative process caused by random accrual of cellular damage over time. In spite of this, age can be accurately estimated by epigenetic clocks based on DNA methylation profiles from almost any tissue of the body. Since such pan-tissue epigenetic clocks have been successfully developed for several different species, it is difficult to ignore the likelihood that a defined and shared mechanism instead, underlies the aging process. To address this, we generated 10,000 methylation arrays, each profiling up to 37,000 cytosines in highly-conserved stretches of DNA, from over 59 tissue-types derived from 128 mammalian species. From these, we identified and characterized specific cytosines, whose methylation levels change with age across mammalian species. Genes associated with these cytosines are greatly enriched in mammalian developmental processes and implicated in age-associated diseases. From the methylation profiles of these age-related cytosines, we successfully constructed three highly accurate universal mammalian clocks for eutherians, and one universal clock for marsupials. The universal clocks for eutherians are similarly accurate for estimating ages (r>0.96) of any mammalian species and tissue with a single mathematical formula. Collectively, these new observations support the notion that aging is indeed evolutionarily conserved and coupled to developmental processes across all mammalian species - a notion that was long-debated without the benefit of this new and compelling evidence.

https://www.biorxiv.org/content/10.1101/2021.01.18.426733v1.full

Gene therapy using adeno-associated virus (AAV) as a vector has emerged as a novel therapeutic modality that has the potential to lead to substantial disease modification in many monogenic disorders, or perhaps even cures. Given the interest in the approach, which has been boosted by the recent approval of two AAV-based gene therapies by the US FDA, we have conducted a systematic review of the landscape of clinical trials of AAV-based gene therapies (see Supplementary Fig. 1 and Supplementary Table 1 for details). Here, we highlight the key trends and discuss the implications.

https://www.nature.com/articles/d41573-021-00017-7?fbclid=IwAR3BAMxhp5oHuEXSgsYrCXtlFzZfHevA09BHGa8cGJPameIw8xYmnWYLwvI

Dear Followers!

We are pleased to announce the first 1700 customers of our BMI Disease Tracker app (for Android) https://play.google.com/store/apps/details?id=com.application.bmiobesity&hl=en_US

Please download it and you will have a second opinion on your health state, based on AI & Big Data. You can track your quality of life bio parameters online, remotely. You will get 16 severe diseases risks calculations & 26 personal recommendations how to avoid these risks.

More than 55% of the users are from India (the Facebook campaign was successful).

Today we got 28 000 subscribers to this channel, dedicated to longevity and immortality in Telegram.

We are still recruiting developers (back end, iOS, data scientists). We invite life scientists, pediatricians, advisors.

We will be glad to receive your responses.

Thank you

We recommend to read this book on anti-aging researches:

https://www.amazon.com/Pessimistic-Guide-Anti-aging-Research/dp/1527534359?fbclid=IwAR1zInKYYX-0Z869aRQ_HEtkZ6FMPjbDHdSv9v4UR49X4g74tnLPtyG0Kd8

One of our advisers just sent:

For the next 10 days, our attention will be focused on the American biopharmaceutical company G1 Therapeutics, which is developing low-molecular-weight therapeutics for the treatment of cancer patients.
Their portfolio includes treecycle and intumescent. In 2020, G1 transferred the exclusive rights to its third drug, lerocyclib, to EQRx and Genor Biopharma to market the drug in the US, EU, and Asia-Pacific. As a result, G1 should receive over $300 million and royalties from future sales of the drug.

On Friday, GTHX shares were trading at around $28. In the near future, we can expect a significant increase in the share price, given the high probability of approval by the FDA of the main drug G1 for patients receiving chemotherapy — trilaciclib (trilaciclib).

It is a small molecule inhibitor of cyclin-dependent kinases (CDK4/6) - enzymes involved in cell cycle control and oncogenesis. The first drug in its class to be awarded the status of "breakthrough therapy" by the FDA. Trilaciclib is a myeloprotector designed to improve the immune system of patients on the background of chemotherapy by reducing myelosuppression caused by chemotherapy drugs. Positive data on the effectiveness of the drug were obtained as a result of randomized trials in small cell lung cancer (SCLC) and in metastatic breast cancer with a triple-negative phenotype (mTNBC).

The FDA in August 2020 has already accepted an application for treatment with trilacyclib in patients with SCLC and assigned the drug Priority Review status, which means that the drug will be considered by the FDA in the next 6 months.

On February 15, 2021, in accordance with US laws, G1 is scheduled to pay a fee for new prescription drugs (the so-called PDUFA procedure) in order to conduct a review procedure and possible approval of tetracyclib. This means that there is a high chance of obtaining approval from the FDA for trilacyclib in the near future.

Prior to FDA approval, trilacyclib is already used for patients with SCLC in the United States who cannot participate in CI and for whom there are no suitable alternative therapies. CI with the use of trilaciclib is also performed in other types of tumors and chemotherapy regimens, in order to assess the effectiveness of the drug in maintaining the state of the immune system (reducing myelosuppression) and antitumor effectiveness in combination with chemotherapy.

Rintodestrant is the second G1 drug in the earlier stages of development. It is an oral SERD inhibitor that selectively degrades estrogen receptors, leading to effective blocking of the estrogen signaling pathway, which is important in the treatment of certain estrogen-dependent cancers, primarily for breast cancer with the ER+ phenotype (estrogen-receptor positive). However, rintodestrant already has a strong competitor — the FDA-approved drug fulvestrant.

And here is another argument in favor of G1 Therapeutics-collaboration with such giants as Pfizer. If approved tilatequila, we would not be surprised if G1 shares will be traded in the range of $90-130 per piece.

#OL_BiotechStockMarket #G1_Stock

Olga Borisova:

STERILE INFLAMMATION AND MITOCHONDRIA

Sterile inflammation is the most unpleasant and constant companion of aging. Mitochondria are the most important stimulator of sterile inflammation in all its many pathways.

1. Mitochondria are very similar to bacteria. As soon as their integrity is violated, they launch all sorts of inflammatory pathways.

Mitochondrial DNA triggers inflammation in three ways:

* Activates the" platform of inflammation " of the inflammasome, which releases the pro-inflammatory cytokines Il1beta, Il-18; acts through the standard NF-kb pathway via TNFalpha and Il6, triggers another extracellular DNA sensor (cGAS-STING)

• A phospholipid inner membrane mitochondria —cardiolipin, typically bacterial.

* Excess ROS in mitochondrial dysfunction also stimulates inflammation.

2. It is the direct responsibility of the mitochondria to trigger inflammation during a viral invasion
, they work as "chain dogs".»
immunity. Activation of retrotransposons with age can trigger a mitochondrial "false alarm".

3. Mitochondria are involved in metabolic reprogramming during T-cell differentiation. If the mitochondria do not work well in T cells, they produce Th1, which secrete Ifn-gamma with all their might, leading to a type 1 cytokine storm.

Total: anti-inflammatory therapy should necessarily include work with mitochondrial dysfunction. Here, of course, I would very much like to give the perfect recipe, which, unfortunately, is not available. There are several directions that can be combined, so I've sketched them out.

Anti-inflammatory therapy that targets mitochondria can be targeted at:
1️⃣Reducing leakage and / or neutralizing free radicals;
2️ ⃣ Cardiolipin stabilization;
3. Stimulating mitophagy (neutralizes damaged mitochondria, which means that it prevents the leakage of mtDNA and cardiolipin);
4️ ⃣ Inhibition of inflamasome assembly and "neutralization" of TNFɑ and Il-6 may also be targeted, but this approach is part of the "classical" anti-inflammatory therapy. Although inflammasome is from the newer.

The fight against radicals
From the huge abundance of different drugs, melatonin, NAC, sartans, soft mitochondrial disconnectors, and NAD+precursors perform well. Hormone replacement therapy with estrogens would also be included here.

Mitophagy Inducers
They are certainly the future and recently there was a review about mitophagy. Of the known ones, this is urolitin, spermidine, the same soft disconnectors, hypoxia.

Cardiolipin Stabilizers
It is also very important and still difficult. So far, SS31 (elamipretide) is in this area, and there are different ideas for using phosphatidylcholine/saturated phosphatidylcholine.

This is the picture that turns out.г

Dear followers, we made the first short educational video with longevity rules. Here is rule number one made on the case of Steve Jobs. We plan to make a series of such simple rules so people can increase their chance to reach at least 100 years. Ideas for next videos are highly appreciated.

As we all know in early nineties the chance to reach 100 for an average person was 1%, now - it’s 50%+ Please share your comments on this video:

https://youtu.be/jWYttahHzvc

Our advisor posted this news on 3 February.

Fresh mitochondrial company.

California-based startup Mitrix this week secured $250,000 in pre-funding to embark on its mission to develop “whole-body mitochondrial transfusion”technology.

The company is the first investment of the R42 AI and Longevity fund Ronjon Nag, which shared a 50/50 round with Peter Schramek's Longevity Tech Fund.

This is the second company in the last month with a mitochondrial transplant. The case is becoming an important trend.

New mitochondria drug development event. Quite expensive for such event, but still:

https://mitochondria-targets.com/?fbclid=IwAR0Wskrv57YhOB7sPfBi86Ni3CanxUcUn4reitfFI0laJDwhX2j_EuPMn3A